BioCentury
ARTICLE | Strategy

Life after amylin

August 7, 2006 7:00 AM UTC

Nearly 20 years after its founding to pursue the amylin hormone for diabetes, Amylin Pharmaceuticals Inc. has embarked on a plan to occupy the peptide hormone space, where it believes it can create a product franchise in metabolic and other complex disease states even if others have tried and moved on.

Amylin, founded in 1987, spent more than a decade focused on amylin and another peptide hormone, exendin-4 - including a trip through the valley of death after amylin got bogged down in Phase III trials in the late 1990s. ...